Stockreport

Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples

Mainz Biomed B.V.  (MYNZ) 
PDF BERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of ca [Read more]